Search

Displaying results 3681 - 3690 of 5925 in total
  1. Drug

    Nifuroquine

    go.drugbank.com/drugs/DB19999
    Experimental

    Nifuroquine has a monoisotopic molecular weight of 300.04 Da.

  2. Drug

    Semparatide

    go.drugbank.com/drugs/DB20016
    Experimental

    Semparatide has a monoisotopic molecular weight of 4002.26 Da.

  3. Drug

    Brobactam

    go.drugbank.com/drugs/DB20131
    Experimental

    Brobactam has a monoisotopic molecular weight of 278.96 Da.

    Synonyms: Sulbactam related compound d, Sulbactam sodium impurity d
  4. Drug

    Fandosentan

    go.drugbank.com/drugs/DB20193
    Experimental

    Fandosentan has a monoisotopic molecular weight of 517.08 Da.

  5. Drug

    Talorasib

    go.drugbank.com/drugs/DB21686
    Experimental

    Talorasib has a monoisotopic molecular weight of 604.24 Da.

  6. Drug

    Human interferon beta

    go.drugbank.com/drugs/DB14999
    ApprovedInvestigational

    [L12078] Interferon-beta has been used in the past in clinical studies with other coronaviruses due to its demonstrated activity against the virus causing Middle Eastern Respiratory Syndrome (MERS).

  7. Drug

    Zuranolone

    go.drugbank.com/drugs/DB15490
    ApprovedInvestigational

    Unlike other more common GABA<sub>A</sub> positive allosteric modulators on the market like benzodiazepines, zuranolone can modulate both synaptic and extrasynaptic GABA<sub>A</sub> conductance due to

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Gatifloxacin

    go.drugbank.com/drugs/DB01044
    ApprovedInvestigationalWithdrawn

    The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence

    Mixtures: GATIPHARM - D® (GATIFLOXACINA 0.3% + DEXAMETASONA 0.1% SOLUCIÓN OFTÁLMICA ESTERIL), GATIPHARM - D® (GATIFLOXACINA 0.3% + DEXAMETASONA 0.1% SOLUCIÓN OFTÁLMICA ESTERIL)Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 Inhibitors
  9. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed. It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness ...

  10. Drug

    Gestrinone

    go.drugbank.com/drugs/DB11619
    Approved

    However, from 1982 this drug attracted increased interest due to significant therapeutic effects in the treatment endometriosis.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates